0000950123-11-020500.txt : 20110418 0000950123-11-020500.hdr.sgml : 20110418 20110301143424 ACCESSION NUMBER: 0000950123-11-020500 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20110301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CHAMPIONS BIOTECHNOLOGY, INC. CENTRAL INDEX KEY: 0000771856 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 521401755 STATE OF INCORPORATION: DE FISCAL YEAR END: 0430 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 855 N. WOLFE STREET STREET 2: SUITE 619 CITY: BALTIMORE STATE: MD ZIP: 21205 BUSINESS PHONE: 410-369-0365 MAIL ADDRESS: STREET 1: 855 N. WOLFE STREET STREET 2: SUITE 619 CITY: BALTIMORE STATE: MD ZIP: 21205 FORMER COMPANY: FORMER CONFORMED NAME: CHAMPIONS BIOTECHNOLOGY, INC. DATE OF NAME CHANGE: 20070220 FORMER COMPANY: FORMER CONFORMED NAME: CHAMPIONS SPORTS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: INTERNATIONAL GROUP INC DATE OF NAME CHANGE: 19860319 CORRESP 1 filename1.htm Correspondence
Champions Biotechnology, Inc.
855 North, Wolfe Street, Suite 619
Baltimore, Maryland 21205
(410) 369-0365
March 1, 2011
Via EDGAR
Jeffrey Riedler
Assistant Director
Division of Corporate Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
RE:   Champions Biotechnology, Inc. (the “Company”)
Preliminary Information Statement on Schedule 14C
Filed February 23, 2011
File No. 001-17263
Dear Mr. Riedler:
I am writing to you in response to your letter of March 1, 2011 regarding the above referenced filing. Below is the Company’s response to the comment raised.
Adoption of the 2010 Equity Incentive Plan, page 9
1. We note your comment and will revise our filing accordingly.
General
The Company hereby acknowledges that the Company is responsible for the adequacy and accuracy of the disclosure in the filing, and staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing. The Company further acknowledges that the Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

 

 

 

Jeffrey Riedler
Division of Corporation Finance
Securities and Exchange Commission
March 1, 2011
Page 2
Should you require any further information or have additional comments, please contact me.
         
  Sincerely,


CHAMPIONS BIOTECHNOLOGY, INC.
 		  
  /s/ Joel Ackerman    
  Joel Ackerman   
  Chief Executive Officer   
 
     
cc:  
Ms. Karen Ubell
Division of Corporate Finance
   
Securities and Exchange Commission
   
Via fax (202) 772-9198
   
Hillel Tendler
Neuberger, Quinn, Gielen, Rubin & Gibber